Cargando…
Development of a T‐cell receptor multimer with high avidity for detecting a naturally presented tumor‐associated antigen on osteosarcoma cells
For efficacy of peptide vaccination immunotherapy for patients with cancer, endogenous expression of the target peptide/human leukocyte antigen (HLA) on cancer cells is required. However, it is difficult to evaluate the expression status of a peptide/HLA complex because of the lack of a soluble T‐ce...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317924/ https://www.ncbi.nlm.nih.gov/pubmed/30375705 http://dx.doi.org/10.1111/cas.13854 |
_version_ | 1783384798807457792 |
---|---|
author | Watanabe, Kazue Tsukahara, Tomohide Toji, Shingo Saitoh, Shogo Hirohashi, Yoshihiko Nakatsugawa, Munehide Kubo, Terufumi Kanaseki, Takayuki Kameshima, Hidekazu Terui, Takeshi Sato, Noriyuki Torigoe, Toshihiko |
author_facet | Watanabe, Kazue Tsukahara, Tomohide Toji, Shingo Saitoh, Shogo Hirohashi, Yoshihiko Nakatsugawa, Munehide Kubo, Terufumi Kanaseki, Takayuki Kameshima, Hidekazu Terui, Takeshi Sato, Noriyuki Torigoe, Toshihiko |
author_sort | Watanabe, Kazue |
collection | PubMed |
description | For efficacy of peptide vaccination immunotherapy for patients with cancer, endogenous expression of the target peptide/human leukocyte antigen (HLA) on cancer cells is required. However, it is difficult to evaluate the expression status of a peptide/HLA complex because of the lack of a soluble T‐cell receptor (TCR) that reacts with tumor‐associated antigen (TAA) with high avidity. In the present study, we developed two soluble TCR‐multimers that were each directed to TAA, survivin‐2B (SVN‐2B) and PBF in the context of HLA‐A24 (SVN‐2B TCR‐multimer and PBF TCR‐multimer, respectively), from CTL clones that were established from peptide‐vaccinated patients. Both TCR multimers could recognize cognate peptide‐pulsed antigen‐presenting cells, C1R‐A24 cells, in a CD8‐independent method. Moreover, the PBF TCR‐multimer successfully recognized a PBF peptide naturally presented on HLA‐A24(+) PBF (+) osteosarcoma cells. Taken together, the results indicated that a TCR‐multimer might be useful for detection of a TAA‐derived peptide presented by HLA in patients receiving immunotherapy. |
format | Online Article Text |
id | pubmed-6317924 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-63179242019-01-08 Development of a T‐cell receptor multimer with high avidity for detecting a naturally presented tumor‐associated antigen on osteosarcoma cells Watanabe, Kazue Tsukahara, Tomohide Toji, Shingo Saitoh, Shogo Hirohashi, Yoshihiko Nakatsugawa, Munehide Kubo, Terufumi Kanaseki, Takayuki Kameshima, Hidekazu Terui, Takeshi Sato, Noriyuki Torigoe, Toshihiko Cancer Sci Original Articles For efficacy of peptide vaccination immunotherapy for patients with cancer, endogenous expression of the target peptide/human leukocyte antigen (HLA) on cancer cells is required. However, it is difficult to evaluate the expression status of a peptide/HLA complex because of the lack of a soluble T‐cell receptor (TCR) that reacts with tumor‐associated antigen (TAA) with high avidity. In the present study, we developed two soluble TCR‐multimers that were each directed to TAA, survivin‐2B (SVN‐2B) and PBF in the context of HLA‐A24 (SVN‐2B TCR‐multimer and PBF TCR‐multimer, respectively), from CTL clones that were established from peptide‐vaccinated patients. Both TCR multimers could recognize cognate peptide‐pulsed antigen‐presenting cells, C1R‐A24 cells, in a CD8‐independent method. Moreover, the PBF TCR‐multimer successfully recognized a PBF peptide naturally presented on HLA‐A24(+) PBF (+) osteosarcoma cells. Taken together, the results indicated that a TCR‐multimer might be useful for detection of a TAA‐derived peptide presented by HLA in patients receiving immunotherapy. John Wiley and Sons Inc. 2018-12-01 2019-01 /pmc/articles/PMC6317924/ /pubmed/30375705 http://dx.doi.org/10.1111/cas.13854 Text en © 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Watanabe, Kazue Tsukahara, Tomohide Toji, Shingo Saitoh, Shogo Hirohashi, Yoshihiko Nakatsugawa, Munehide Kubo, Terufumi Kanaseki, Takayuki Kameshima, Hidekazu Terui, Takeshi Sato, Noriyuki Torigoe, Toshihiko Development of a T‐cell receptor multimer with high avidity for detecting a naturally presented tumor‐associated antigen on osteosarcoma cells |
title | Development of a T‐cell receptor multimer with high avidity for detecting a naturally presented tumor‐associated antigen on osteosarcoma cells |
title_full | Development of a T‐cell receptor multimer with high avidity for detecting a naturally presented tumor‐associated antigen on osteosarcoma cells |
title_fullStr | Development of a T‐cell receptor multimer with high avidity for detecting a naturally presented tumor‐associated antigen on osteosarcoma cells |
title_full_unstemmed | Development of a T‐cell receptor multimer with high avidity for detecting a naturally presented tumor‐associated antigen on osteosarcoma cells |
title_short | Development of a T‐cell receptor multimer with high avidity for detecting a naturally presented tumor‐associated antigen on osteosarcoma cells |
title_sort | development of a t‐cell receptor multimer with high avidity for detecting a naturally presented tumor‐associated antigen on osteosarcoma cells |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317924/ https://www.ncbi.nlm.nih.gov/pubmed/30375705 http://dx.doi.org/10.1111/cas.13854 |
work_keys_str_mv | AT watanabekazue developmentofatcellreceptormultimerwithhighavidityfordetectinganaturallypresentedtumorassociatedantigenonosteosarcomacells AT tsukaharatomohide developmentofatcellreceptormultimerwithhighavidityfordetectinganaturallypresentedtumorassociatedantigenonosteosarcomacells AT tojishingo developmentofatcellreceptormultimerwithhighavidityfordetectinganaturallypresentedtumorassociatedantigenonosteosarcomacells AT saitohshogo developmentofatcellreceptormultimerwithhighavidityfordetectinganaturallypresentedtumorassociatedantigenonosteosarcomacells AT hirohashiyoshihiko developmentofatcellreceptormultimerwithhighavidityfordetectinganaturallypresentedtumorassociatedantigenonosteosarcomacells AT nakatsugawamunehide developmentofatcellreceptormultimerwithhighavidityfordetectinganaturallypresentedtumorassociatedantigenonosteosarcomacells AT kuboterufumi developmentofatcellreceptormultimerwithhighavidityfordetectinganaturallypresentedtumorassociatedantigenonosteosarcomacells AT kanasekitakayuki developmentofatcellreceptormultimerwithhighavidityfordetectinganaturallypresentedtumorassociatedantigenonosteosarcomacells AT kameshimahidekazu developmentofatcellreceptormultimerwithhighavidityfordetectinganaturallypresentedtumorassociatedantigenonosteosarcomacells AT teruitakeshi developmentofatcellreceptormultimerwithhighavidityfordetectinganaturallypresentedtumorassociatedantigenonosteosarcomacells AT satonoriyuki developmentofatcellreceptormultimerwithhighavidityfordetectinganaturallypresentedtumorassociatedantigenonosteosarcomacells AT torigoetoshihiko developmentofatcellreceptormultimerwithhighavidityfordetectinganaturallypresentedtumorassociatedantigenonosteosarcomacells |